CVS - CVS Health Corporation

NYSE - NYSE Delayed Price. Currency in USD
65.26
-0.88 (-1.33%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close66.14
Open65.75
Bid0.00 x 0
Ask0.00 x 0
Day's Range65.06 - 65.98
52 Week Range60.14 - 84.00
Volume6,341,221
Avg. Volume8,749,776
Market Cap66.347B
Beta0.90
PE Ratio (TTM)10.01
EPS (TTM)6.52
Earnings DateAug 8, 2018
Forward Dividend & Yield2.00 (2.96%)
Ex-Dividend Date2018-04-20
1y Target Est85.89
Trade prices are not sourced from all markets
  • CVS apologizes after transgender woman says she was denied hormone prescription
    CBS MoneyWatchyesterday

    CVS apologizes after transgender woman says she was denied hormone prescription

    The pharmacist "kept asking, loudly and in front of other CVS staff and customers, why I was given the prescriptions," the woman wrote

  • See what the IHS Markit Score report has to say about CVS Health Corp.
    Markit2 days ago

    See what the IHS Markit Score report has to say about CVS Health Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Analysts Expect Drug Supplier Whiplash To Endure on Rebate Changes
    Bloomberg2 days ago

    Analysts Expect Drug Supplier Whiplash To Endure on Rebate Changes

    Analysts agree Trump’s prescription drug plans look ugly -- but they are divided on the real financial impact of the changes on the pharmaceutical supply chain. While Jefferies expects the rebates debate to be an overhang, they only see a “modestly negative” impact in the worst case scenario, with Medicare beneficiaries and the federal government shouldering the bulk of the costs if rebates were eliminated. “The fundamental impact of an elimination of Medicare Part D rebates will likely be neutral to just modestly negative.” Removing drug rebates “may reduce competitive bidding advantage for CVS, ESRX, and UNH (Optum) in Part D.” Jefferies expects the sector to “trade sideways at best” for the near-term.

  • CNBC3 days ago

    Albertsons and Rite Aid have a message for investors: Size still matters

    The combination would create a new retail giant valued at roughly $24 billion. The companies think their combined size will make them more competitive against mega-giants Walmart and Amazon. As Albertsons Cos. and Rite Aid RAD head to an August vote over their planned merger, the message to investors is simple: size still matters.

  • This week in NYC funding news: Naadam, Perch, CyberMDX, AbleTo
    American City Business Journals3 days ago

    This week in NYC funding news: Naadam, Perch, CyberMDX, AbleTo

    Corporate venture capital firms have some advice for startups. Reach out to corporate VCs as early as possible, advised Motorola Solutions' Gopal Rajaraman . Behavioral health startup AbleTo is under new stewardship.

  • Trump's Drug-Price Push Butts Into Two Megadeals
    Bloomberg3 days ago

    Trump's Drug-Price Push Butts Into Two Megadeals

    Donald Trump’s drug-price push is steering right into health megadeals. The Trump administration’s budget office was sent a proposal by the Health and Human Services Department late Wednesday that seems to target pharmacy benefit managers — the middlemen in the pricing process — as part of efforts to change the way drugs are paid for.

  • MarketWatch3 days ago

    Shares of U.S. pharmacy middlemen drop on threat to rebates

    MARKET PULSE A policy being weighed by the Trump administration that could threaten drug price rebates, a widespread feature of the U.S. pharmaceutical system that largely benefits pharmaceutical middlemen, sent shares of those companies down in Thursday trade.

  • PR Newswire5 days ago

    CVS Health Expands Commitment to Veterans Transitioning to Civilian Life

    WOONSOCKET, R.I., July 18, 2018 /PRNewswire/ -- In its continuing commitment to hire our nation's veterans, CVS Health (CVS) today announced the expansion of the company's participation in the Department of Defense SkillBridge Initiative, which helps service men and women transition from military life to private sector civilian careers, to new locations in Hampton Roads (Virginia) and Schofield Barracks (Hawaii). Active duty military at these bases can begin training with CVS Health within 180 days of their separation from military service. "The U.S. Department of Defense estimates approximately 1,300 new veterans and their families return to civilian life every day, many of whom are looking for the opportunity to find meaningful employment after serving," said Lisa Bisaccia, Executive Vice President and Chief Human Resources Officer, CVS Health.

  • Zacks.com featured highlights include: ConocoPhillips, Archer Daniels, CVS, Fortinet and Avnet
    Zacks5 days ago

    Zacks.com featured highlights include: ConocoPhillips, Archer Daniels, CVS, Fortinet and Avnet

    Zacks.com featured highlights include: ConocoPhillips, Archer Daniels, CVS, Fortinet and Avnet

  • The Zacks Analyst Blog Highlights: CVS, RH, Groupon, Darden and Carrols
    Zacks5 days ago

    The Zacks Analyst Blog Highlights: CVS, RH, Groupon, Darden and Carrols

    The Zacks Analyst Blog Highlights: CVS, RH, Groupon, Darden and Carrols

  • CVS, Walgreens, Walmart object to proposed tax on Mass. retail clinics
    American City Business Journals5 days ago

    CVS, Walgreens, Walmart object to proposed tax on Mass. retail clinics

    A national lobbying group representing retail clinics and urgent care companies have joined Massachusetts business groups to oppose a proposed an 8.75 percent tax on assessed charges on walk-in clinics.

  • 4 Retail Stocks to Buy as Q2 Earnings Season Knocks
    InvestorPlace5 days ago

    4 Retail Stocks to Buy as Q2 Earnings Season Knocks

    Per the latest Earnings Preview, total earnings for the S&P 500 index is expected to rise 19% in second-quarter 2018, with 11 of the 16 Zacks sectors likely to register double-digit earnings growth. The Zacks Consensus Estimate for the quarter is pegged at 76 cents.

  • AbleTo poaches CVS exec for top position
    American City Business Journals5 days ago

    AbleTo poaches CVS exec for top position

    Trip Hofer, who led CVS' specialty pharmacy division, has stepped into the role of CEO at New York-based AbleTo.

  • 5 Stocks Trading Near 52-Week High With More Room to Run
    InvestorPlace5 days ago

    5 Stocks Trading Near 52-Week High With More Room to Run

    More often than not, investors wonder if the high price range has made the stock overpriced. In fact, in an attempt to avoid stocks that are trading near their 52-week high levels, an investor might miss out on top gainers. This is because investors fear that the stocks are overvalued and a price crash is impending.

  • Zacks6 days ago

    Banks Keep Dow in the Green While the Rest Stumble

    Banks Keep Dow in the Green While the Rest Stumble

  • See what the IHS Markit Score report has to say about CVS Health Corp.
    Markit6 days ago

    See what the IHS Markit Score report has to say about CVS Health Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Americans on a Spring Spending Spree: Top 5 Gainers
    Zacks6 days ago

    Americans on a Spring Spending Spree: Top 5 Gainers

    Big burst of spending in spring after a ho-hum winter is primarily backed by Trump's tax cuts, strong hiring and declining unemployment rate.

  • PR Newswire6 days ago

    CVS Health Responds to Request for Information on Trump Administration's Blueprint to Lower Drug Prices

    WOONSOCKET, R.I., July 16, 2018 /PRNewswire/ -- CVS Health (CVS) today submitted its comments in response to the Request for Information (RFI) on the Trump Administration's Blueprint to Lower Drug Prices.  In a cover letter to Secretary of Health and Human Services (HHS) Alex Azar summarizing the full comments submitted to HHS, the company underscored support for the Administration's goals and emphasized the industry-leading steps it has taken to hold down drug costs and bring innovative solutions to market to help consumers.

  • Associated Press6 days ago

    Correction: CVS-Black Customer story

    CHICAGO (AP) — In a story July 15 about a CVS manager who called police on a black customer, The Associated Press erroneously reported he was a state delegate for Donald Trump's 2016 presidential campaign. The manager claimed on a campaign website that he was a Trump delegate, but the Illinois Republican Party said he wasn't a delegate to the Republican National Convention.

  • Who Caught Analysts’ Eye in the Consumer Sector Last Week?
    Market Realist6 days ago

    Who Caught Analysts’ Eye in the Consumer Sector Last Week?

    On July 12, Costco Wholesale (COST) reported its June sales results. The company reported an 11.7% rise in net sales to $13.5 billion in June compared to its net sales of $12.13 billion in the same period last year.

  • Why Did CVS Health Corporation Shares Lose 11% in 2018?
    Motley Fool6 days ago

    Why Did CVS Health Corporation Shares Lose 11% in 2018?

    The company appears to have a major new competitor.

  • CVS Apologizes After White Manager Called Police on Black Customer Over Coupon
    Fortune7 days ago

    CVS Apologizes After White Manager Called Police on Black Customer Over Coupon

    The customer was accused of counterfeiting a coupon.

  • Moody's9 days ago

    LB Commercial Trust 1998-C4 -- Moody's Upgrades Two Classes and Affirms Two Classes of LBCMT 1998-C4

    The rating on two P&I classes were upgraded primarily due to an increase in credit support since Moody's last review, resulting from paydowns and amortization, as well as Moody's expectation of additional increases in credit support resulting from the payoff of loans approaching maturity that are well positioned for refinance. The pool has paid down by 48% since Moody's last review. The rating on Cl. L was affirmed because the ratings are consistent with Moody's expected loss plus realized losses.

  • Motley Fool9 days ago

    Are We on the Cusp of a Big Alzheimer's Disease Breakthrough?

    One of Biogen's drugs could put us on a path to delaying disease progression.